San Diego, Monday, 15 September 2025.aTyr Pharma reports significant Phase 3 trial success for efzofitimod in treating pulmonary sarcoidosis, causing a 7.5% stock surge and positioning the company as

Atyr PHARMA INC (NASDAQ:ATYR - Free Report) - HC Wainwright cut their Q3 2025 earnings per share estimates for Atyr PHARMA in a report issued on Thursday, May 8th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings of ($0.19) per share for the quarter, down from

Get more from THE OPTIONS BULLY on Patreon

Pomerantz Law Firm is urging aTyr Pharma's investors who faced losses to participate in a class action lawsuit. Important deadlines approaching.

The DJS Law Group is investigating securities fraud claims against aTyr Pharma, following a significant drop in shares after a failed drug test.

aTyr's ATYR0101 demonstrates powerful anti-fibrotic effects in lung and kidney models through unique mechanism, marking potential advancement in fibrosis treatment landscape.

Pomerantz Law Firm is conducting an investigation into potential claims against aTyr Pharma, Inc. Following a significant stock drop after a study failure announcement.

Get more from THE OPTIONS BULLY on Patreon

Novel lung disease therapy completes largest-ever sarcoidosis trial, promising alternative to steroids. Topline results from 268-patient study coming Q3. Get insights.

Shareholders of aTyr Pharma Inc. are being given a unique chance to spearhead a securities fraud class action lawsuit after significant losses.

Shareholders of aTyr Pharma, Inc. who incurred losses are encouraged to join a class action lawsuit led by Levi & Korsinsky, LLP, aiming for compensation.

aTyr Pharma (NASDAQ: ATYR) reported its Q1 2025 results and provided key updates on its clinical programs. The company's flagship Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis is progressing well, with topline data expected in Q3 2025. The study enrolled 268 patients across 85 centers in nine countries. The company's Phase 2 EFZO-CONNECT™ study for systemic sclerosis-related ILD continues enrollment, with interim data expected in Q2 2025. Financially, aTyr reported $78.8 million in cash and investments as of March 31, 2025, with R&D expenses of $11.8 million and G&A expenses of $4.0 million for Q1. The company appointed Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise and will present important data at the upcoming ATS 2025 International Conference.

aTyr Pharma's efzofitimod fails Phase 3 trial in pulmonary sarcoidosis, with shares dropping 80%. Drug didn't show significant improvement in steroid reduction vs placebo.

aTyr's efzofitimod shows unique NRP2-targeting mechanism in prestigious Science publication, advancing Phase 3 trials for pulmonary sarcoidosis and rare lung diseases.

Levi & Korsinsky, LLP alerts investors about a class action lawsuit against aTyr Pharma, with a deadline of December 8, 2025, for participation.

Levi & Korsinsky, LLP highlights an impending deadline for aTyr Pharma investors in a securities class action lawsuit, urging affected shareholders to act.